"目录号: HY-15283
GPCR/G Protein-
Clopidogrel是口服活性的P2Y12受体阻断剂。
P2Y Receptor
相关产品
Suramin sodium salt-Clopidogrel hydrogen sulfate-Ticagrelor-MRS 2578-Prasugrel-AZD1283-N6-(4-Hydroxybenzyl)adenosine-Diquafosol tetrasodium-Denufosol tetrasodium-
生物活性
Description
Clopidogrel is a well-known P2Y12 receptor blocker.IC50 value:Target: P2Y12 receptorClopidogrel (INN) is an oral, thienopyridine class antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi under the trade name Plavix. The drug works by irreversibly inhibiting a receptor called P2Y12, an adenosine diphosphate (ADP) chemoreceptor on platelet cell membranes. Adverse effects include hemorrhage, severe neutropenia, and thrombotic thrombocytopenic purpura (TTP). From Wikipedia
Clinical Trial
NCT01341600
University of Maryland-Food and Drug Administration (FDA)-National Cancer Institute (NCI)-National Institute of General Medical Sciences (NIGMS)
Metabolism of Clopidogrel
July 2010
NCT01503658
Seoul National University Hospital
Influence of Genotype of Drug Metabolizing Enzyme or Transporter on the Pharmacokinetics/Pharmacodynamics of Clopidogrel-Influence of Aspirin on the Pharmacokinetics/Pharmacodynamics of Clopidogrel
January 2012
Phase 4
NCT02185534
AstraZeneca
Bioequivalence, AUC, Cmax, Pharmacokinetics
August 2014
Phase 1
NCT02048228
Chinese PLA General Hospital
CLOPIDOGREL, POOR METABOLISM of (Disorder)
October 2014
Phase 2-Phase 3
NCT01097343
University of North Carolina, Chapel Hill
Disease Susceptibility
March 2010
Phase 2
NCT01960296
Icahn School of Medicine at Mount Sinai-Doris Duke Charitable Foundation
Clopidogrel
January 2012
Phase 2
NCT02010632
Khon Kaen University
Pharmacodynamics
August 2013
Phase 1
NCT01512485
Dr. Reddy's Laboratories Limited
Healthy
October 2006
Phase 1
NCT01493999
University of Pecs
Acute Coronary Syndrome
September 2011
Phase 4
NCT02628587
Hospital Central San Luis Potosi, Mexico
Acute Coronary Syndrome
February 2016
Phase 4
NCT01212302
Ruhr University of Bochum
Coronary Artery Disease
October 2008
NCT00724880
Catharina Ziekenhuis Eindhoven
Coronary Artery Disease
June 2006
Phase 4
NCT02411903
The Third Affiliated Hospital of Guangzhou Medical University
Cerebral Infarction-Clopidogrel,Poor Metabolism of (Disorder)
March 2015
Phase 4
NCT00799045
Laval University-Sanofi-Bristol-Myers Squibb
Migraine
October 2008
Phase 4
NCT01094275
Neil Kleiman, MD-The Methodist Hospital System
Coronary Artery Disease
January 2010
Phase 4
NCT01447563
Hospital Universitario Dr. Jose E. Gonzalez
Comparative Bioavailability of Clopidogrel Tablets
May 2008
Phase 1
NCT02054663
Ottawa Heart Institute Research Corporation
Acute Coronary Syndrome
December 2013
Phase 4
NCT02938182
First Affiliated Hospital Xi'an Jiaotong University
Migraine
October 2016
Phase 4
NCT01506713
Dr. Reddy's Laboratories Limited
Fasting
September 2006
Phase 1
NCT03039205
University of Sao Paulo-Fundação de Amparo à Pesquisa do Estado de São Paulo
Platelet Aggregation-Adenosine-Coronary Artery Disease-Kidney Dysfunction-Antiplatelet Therapy
July 1, 2017
Phase 2
NCT01621763
Dr. Reddy's Laboratories Limited
Healthy
September 2008
Phase 1
NCT01129063
Sanofi-Bristol-Myers Squibb
Healthy
March 2009
Phase 1
NCT01621750
Dr. Reddy's Laboratories Limited
Fasting
August 2008
Phase 1
NCT01706510
Rapid City Regional Hospital, Inc-AstraZeneca
Coronary Artery Disease
December 2012
Phase 4
NCT00620646
Samsung Medical Center
Clopidogrel Non-Responsiveness
February 2008
NCT00640679
Deutsches Herzzentrum Muenchen
Coronary Artery Disease
April 2008
Phase 4
NCT02060786
Ajou University School of Medicine-Dong-A Pharmaceutical
Acute Coronary Syndrome
October 2010
Phase 4
NCT00619073
University of Massachusetts, Worcester-Sanofi-Bristol-Myers Squibb
Blood Platelets-Clopidogrel
April 2008
NCT01260584
Daiichi Sankyo Inc.
Coronary Artery Disease
November 2010
Phase 4
NCT02560688
Daiichi Sankyo Inc.
Drug Interaction
December 2015
Phase 1
NCT01955642
Centre Hospitalier Universitaire de Saint Etienne-Groupe de Recherche sur la Thrombose
Brain Ischemia-Ischemic Attack
September 2013
NCT01609647
Dong-A University
Acute Coronary Syndrome
September 2012
Phase 3
NCT02048085
Medical Center of South Arkansas
Acute ST Segment Elevation Myocardial Infarction-Acute Coronary Syndrome
February 2014
Phase 4
NCT02133989
Samsung Medical Center-Yuyu Pharma, Inc.
Carotid Stenosis
June 2014
Phase 3
NCT01743014
AHEPA University Hospital-Aristotle University Of Thessaloniki
Diabetes Type 2-Diabetic Nephropathy-Vascular Disease
July 2012
Phase 4
NCT01806090
Chinese University of Hong Kong
Gastrointestinal Bleeding
February 2012
Phase 4
NCT01421706
Inje University
Healthy
July 2008
Phase 1
NCT00696566
Sheffield Teaching Hospitals NHS Foundation Trust-British Heart Foundation-University of Sheffield
Coronary Artery Disease
November 2007
Phase 1
NCT01011257
Neil Kleiman, MD-The Methodist Hospital System
Coronary Artery Disease
September 2009
Phase 4
NCT01465828
Gennaro Sardella-University of Roma La Sapienza
Acute Coronary Syndrome
October 2011
Phase 3
NCT01663038
Chong Kun Dang Pharmaceutical-Inje University
Coronary Artery Disease
December 2010
Phase 1
NCT02086903
Dong-A University
Pharmacodynamics
February 2014
Phase 3
NCT02469740
University Hospital of Limerick
Myocardial Ischemia-Coronary Artery Disease-Endothelial Dysfunction
July 2015
Phase 4
NCT01283282
Emory University
Coronary Artery Disease
January 2008
Phase 4
NCT00940784
Ronald Hoffman-Myeloproliferative Disorders-Research Consortium-National Cancer Institute (NCI)-Icahn School of Medicine at Mount Sinai
Polycythemia Vera
June 2009
Phase 2
NCT00484926
Seung-Jung Park-CardioVascular Research Foundation, Korea
Coronary Artery Disease
March 2007
Phase 4
NCT00444132
Sheba Medical Center
Clopidogrel Non-Responsiveness
March 2005
Phase 3
NCT01775839
Seoul National University Hospital
DRUG REACTIONS
January 2013
Phase 4
NCT03062462
First Affiliated Hospital of Harbin Medical University
Coronary Artery Disease-Clopidogrel, Poor Metabolism of
February 10, 2017
Phase 2-Phase 3
NCT01014624
Daiichi Sankyo Inc.
Coronary Artery Disease
February 2010
Phase 4